Skip to main content

Table 1 Eligibility criteria

From: Rectally administered indomethacin to prevent post-ESWL-pancreatitis (RIPEP): study protocol for a randomized controlled trial

Any patient with chronic pancreatitis and pancreatic stones (5 mm or more in diameter) undergoing P-ESWL who is at least 18 years old, provides informed consent, and:

Exclusion criteria

 Contraindications to ESWL

 Suspected or established malignancy

 Pancreatic ascites

 Receiving NSAIDs within 7 days

 Contraindication to NSAIDs (including gastrointestinal hemorrhage within 4 weeks or renal dysfunction with serum creatinine > 120 μmol/L)

 Presence of coagulopathy or received anticoagulation therapy within 3 days

 Acute pancreatitis within 3 days

 Known active cardiovascular or cerebrovascular disease

 Unwilling or unable to provide consent

 Pregnant or breastfeeding women

 Being without a rectum (i.e., status post-total proctocolectomy)

  1. ESWL extracorporeal shock wave lithotripsy, NSAIDs nonsteroidal anti-inflammatory drugs, P-ESWL pancreatic extracorporeal shock wave lithotripsy